BPC-157 Dosage: Where the Numbers Came From and What They Mean

Almost every BPC-157 dosing figure in circulation traces back to rat studies, and almost nobody says so. The protocols quoted on vendor sites and in forum posts are allometric conversions from animal work, not the output of human dose finding trials, because those trials have not been run. That does not make the numbers useless. It does mean the confidence attached to them is borrowed rather than earned, and knowing where each figure came from is the difference between following a protocol and understanding one.

This page sets out what the source research actually used, how the commonly quoted human ranges were derived from it, what the practical dosing decisions are, and where the arithmetic goes wrong. If you want the mechanism and the evidence base first, the BPC-157 guide covers both, and the side effect page covers what is and is not documented.

Where the Numbers Come From

The BPC-157 literature is almost entirely preclinical. The rodent work that generated the dosing figures typically used ranges spanning several orders of magnitude, most commonly around 10 micrograms per kilogram and 10 nanograms per kilogram, delivered intraperitoneally, intramuscularly or orally depending on the model. Those two doses appear repeatedly because the original research programme was testing whether effect persisted across a very wide range rather than searching for an optimum.

The commonly quoted human figures are produced by taking the 10 mcg/kg rodent dose and applying body surface area scaling, which is the standard allometric method for converting between species. That conversion divides the rodent dose by roughly 6.2 for a human, which lands near 1.6 mcg/kg, or about 110 micrograms for a 70kg adult.

Then look at what people actually use: 250 to 500 micrograms once or twice daily, which is two to ten times the scaled figure. The gap is not a calculation error. It reflects that community protocols were built from reported experience rather than from the conversion, and that nobody has run the study that would settle which is right. Both numbers are defensible. Neither is validated.

The Dosing Decisions That Actually Matter

Four choices, in descending order of how much they change the outcome.

Route: subcutaneous, intramuscular or oral

This decides more than the number does. Subcutaneous injection into abdominal fat is the default for systemic use and is what most protocols assume. Intramuscular injection near a specific injury is the choice when the target is local rather than systemic, on the theory that tissue concentration at the site matters, although the systemic distribution data does not clearly support the distinction. Oral BPC-157 is a different question entirely, because a peptide crossing the stomach faces conditions designed to break peptides down, and the oral BPC-157 page covers what survives and what the evidence for gut local effect actually is.

Frequency: once or twice daily

BPC-157 has a short plasma half life, plausibly in the range of minutes rather than hours based on the available pharmacokinetic work. If the mechanism depends on sustained exposure, splitting the daily dose is the more logical schedule. If it depends on a signalling event that outlasts the plasma window, once daily is sufficient. Nobody knows which, and dividing the same total dose across two injections is the conservative answer because it costs nothing except an extra injection.

Duration: how long a block runs

Two to four weeks is the commonly used block for an acute injury, extending to six or eight for something slow like a tendon. There is no receptor desensitisation argument forcing a break, unlike the growth hormone secretagogues, so cycling BPC-157 is a precaution rather than a mechanism driven requirement. The cycle length guide covers why some compounds genuinely require an off period and why this one does not obviously belong in that group.

Total daily dose

Last on the list, because it is the variable with the widest defensible range and the weakest evidence for any particular point inside it. Most protocols land between 250 and 500 micrograms daily. Going higher is common and there is no published dose response curve suggesting it helps.

Working Protocols People Actually Use

These are descriptions of what appears in practice, presented as research use information rather than as instructions. None of them is validated in a human trial.

The pattern worth noticing is that the dose barely moves between goals while the route and duration change a lot. That is the honest reflection of the evidence: the literature supports the idea that BPC-157 does something across a very wide dose range, and gives almost no guidance on where inside that range to sit.

Turning Milligrams Into Syringe Units

BPC-157 doses are quoted in micrograms and vials are labelled in milligrams, which is where most of the arithmetic errors live. One milligram is one thousand micrograms, so a 5mg vial contains 5,000 micrograms, which is twenty doses at 250 mcg.

Concentration is vial milligrams divided by millilitres of bacteriostatic water added. Volume per dose is the dose divided by that concentration, with the dose converted to milligrams first. Units are that volume multiplied by 100 on a standard U-100 insulin syringe.

The row worth avoiding is a 10mg vial in 2mL, where a 250 mcg dose lands at five units. That is measurable but unforgiving, because a one unit misread is a twenty percent dosing error. Adding more water pushes the same dose into a part of the barrel that tolerates a small mistake. The BPC-157 dosage calculator runs this for any combination, including the BPC-157 and TB-500 blend.

Injection Site: Does It Matter?

The argument for injecting near an injury is that local tissue concentration is what drives the healing effect, so putting the compound close to the target should help. The argument against is that BPC-157 appears to act systemically through the nitric oxide pathway and by upregulating growth factor receptor expression, both of which are mediated rather than local, and that a peptide with a short plasma half life distributes long before it does anything.

No human study has compared the two. What can be said is that the rodent work showing tendon and ligament effects mostly used systemic administration rather than local injection, which is weak evidence that proximity is not required. Injecting near a site is not harmful and costs nothing, so the practice persists on reasonable grounds. It is just not established.

What does matter is rotating sites. Repeated subcutaneous injection into the same spot produces local irritation and, over a long block, tissue changes that have nothing to do with the compound. The injection guide covers site rotation and technique.

Stacking, and the One Combination That Comes Up Constantly

BPC-157 and TB-500 is the most common pairing in this space, and the logic behind it is sound in outline: the two act through different mechanisms, TB-500 through actin sequestration and cell migration, BPC-157 through angiogenesis and growth factor signalling, so they are not competing for the same pathway. Whether the combination outperforms either alone in humans is unstudied.

Where it gets practically messy is dosing, because TB-500 is dosed weekly in milligrams while BPC-157 is dosed daily in micrograms. A typical pairing runs BPC-157 at 250 to 500 mcg daily alongside TB-500 at 2 to 5mg weekly, often split into two injections. Pre-blended vials exist and remove the flexibility to adjust one without the other, which is a real cost for a small convenience. The TB-500 versus BPC-157 comparison covers which compound suits which injury type, and the stack builder lays out the timing if you are combining more than two things.

Both compounds are stocked by the same suppliers, so a combined order is straightforward: Pantheon TB-500 and Apollo TB500 both list it as a direct product.

Where the Arithmetic Goes Wrong

• Confusing micrograms with milligrams. The single most consequential error available here, because it is a thousandfold. A protocol calling for 250 mcg drawn as 250 mg is not a large dose, it is the entire vial many times over.
• Reading a U-40 syringe as a U-100. The same physical volume reads 2.5 times differently on the two scales. Check the barrel.
• Reusing a concentration from a different vial size. A dose that read as 20 units on the last vial will not read as 20 units on a vial of different strength reconstituted with a different volume. Recalculate every time, and write the concentration on the vial.
• Assuming label weight is peptide weight. Lyophilised powder is typically 70 to 90 percent peptide by mass, with the balance being residual water and counterions. Real doses run modestly below the calculated figure, which the testing guide covers.
• Escalating because nothing happened in week one. Tissue repair timelines are measured in weeks. A dose increase in the first fortnight is a reaction to an interval too short to have produced a result either way.

Key Takeaways

• Every quoted BPC-157 dose descends from rodent studies at 10 mcg/kg and 10 ng/kg, converted rather than measured in humans
• Body surface area scaling from the rodent dose gives about 110 mcg for a 70kg adult, well below what people actually use
• Community protocols cluster at 250 to 500 mcg daily, based on reported experience rather than a dose response curve
• Route and duration change the protocol more than the number does
• Splitting the daily dose is the conservative answer to a short plasma half life and costs only an extra injection
• Reconstitute so that a typical dose lands above ten units on the syringe, because five units is unforgiving
• The microgram to milligram confusion is the error that matters most, and it is a factor of one thousand

For the compound level picture rather than the protocol, the complete guide covers mechanism and evidence, and the tendon repair page covers where BPC-157 sits against the alternatives for that specific use.

Frequently Asked Questions

What is the standard BPC-157 dose?

There is no standard, because no human dose finding trial has been run. Community protocols cluster at 250 to 500 micrograms daily, often split into two subcutaneous injections. Allometric scaling from the rodent studies that generated the original figures suggests something closer to 110 micrograms for a 70kg adult, which is well below what is typically used. Both numbers are defensible and neither is validated.

Should BPC-157 be taken once or twice a day?

The pharmacokinetic work suggests a short plasma half life, plausibly minutes rather than hours, which is an argument for splitting the daily total across two injections. Whether sustained exposure is actually what matters is unknown, because the mechanism may depend on a signalling event that outlasts the plasma window. Splitting the dose is the conservative choice and costs nothing except one extra injection.

How many micrograms are in a 5mg BPC-157 vial?

Five thousand. One milligram is one thousand micrograms, so a 5mg vial holds 5,000 mcg, which is twenty doses at 250 mcg or ten at 500 mcg. A 10mg vial holds 10,000 mcg. This conversion is where the most dangerous dosing error in BPC-157 lives, because confusing the two units is a thousandfold mistake rather than a small one.

How much bacteriostatic water should I use for BPC-157?

Enough that a typical dose lands in a readable part of the syringe, which usually means above ten units on a U-100 barrel. A 5mg vial in 2mL gives 2.5 mg/mL, at which 250 mcg reads as 10 units. A 10mg vial in 2mL gives 5 mg/mL, at which the same dose reads as only 5 units, where a one unit misread is a twenty percent error. Adding more water fixes that without changing how much compound you receive.

Does BPC-157 need to be injected near the injury?

Nobody has compared local and systemic injection in a human study. The rodent work that demonstrated tendon and ligament effects mostly used systemic administration, which is weak evidence that proximity is not required, and the proposed mechanisms are mediated rather than local. Injecting near a site is harmless and costs nothing, so the practice continues on reasonable grounds. It is simply not established.

How long should a BPC-157 block run?

Two to four weeks is common for an acute soft tissue injury and six to eight for slow tissue like tendon or ligament. There is no receptor desensitisation argument forcing a break, unlike the growth hormone secretagogues, so cycling BPC-157 is a precaution rather than a mechanism driven requirement. Judging effect before three to four weeks have passed is judging an interval too short to have produced a result.